Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone

scientific article

Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S11999-017-5451-1
P932PMC publication ID5670060
P698PubMed publication ID28725958

P50authorLeonard B. KabanQ6525086
Zachary S PeacockQ89344252
Soldano FerroneQ90626068
P2093author name stringFrancis J Hornicek
Joseph H Schwab
Ahmad Al-Sukaini
P2860cites workDistinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of boneQ24595521
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerQ24633070
Cancer immunotherapy: the beginning of the end of cancer?Q26752277
MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cellsQ26866479
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaQ27860650
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerQ27860857
Improved Survival with Ipilimumab in Patients with Metastatic MelanomaQ27861062
Do Histologic Criteria Predict Biologic Behavior of Giant Cell Lesions?Q61822198
Maxillofacial and Axial/Appendicular Giant Cell Lesions: Unique Tumors or Variants of the Same Disease?—A Comparison of Phenotypic, Clinical, and Radiographic CharacteristicsQ61822207
A system of staging musculoskeletal neoplasmsQ68720907
Central giant cell lesions of the jaws: a clinicopathologic studyQ68734854
Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus productsQ69621634
Lymphocyte in vitro response to human giant cell tumorsQ71056736
High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progressQ73373427
Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patientsQ79101785
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapyQ80767732
Current status and unanswered questions on the use of Denosumab in giant cell tumor of boneQ28066533
Cancer immunoediting: from immunosurveillance to tumor escapeQ28212251
Giant cell tumor of bone: treatment and outcome of 214 casesQ28271725
12th International Histocompatibility Conference. Genetic diversity of HLA: functional and medical implications. Paris, France, June 9-12, 1996. AbstractsQ28296026
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialQ29620814
Pembrolizumab for the treatment of non-small-cell lung cancerQ29620851
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412Q29622893
The origin of the neoplastic stromal cell in giant cell tumor of boneQ30164416
Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptideQ31152009
The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).Q33765607
Antigen-processing machinery breakdown and tumor growthQ34011098
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interactionQ34298906
B7-h3 and its role in antitumor immunityQ34356712
Properties of the stromal cell in giant cell tumor of boneQ34576537
B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasisQ34935785
Genetic Analysis of Giant Cell Lesions of the Maxillofacial and Axial/Appendicular SkeletonsQ36108604
Cancer immunotherapy: Strategies for personalization and combinatorial approachesQ36387028
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trialQ36929714
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceQ37287152
Clinical importance of B7-H3 expression in human pancreatic cancerQ37424100
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinomaQ37461786
B7-H3 and its relevance in cancer; immunological and non-immunological perspectivesQ37881559
B7-H3-mediated tumor immunology: Friend or foe?Q38135281
Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968Q39222074
Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune responseQ39274136
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activityQ39344502
Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigensQ39572530
Adjuvant Antiangiogenic Treatment for Aggressive Giant Cell Lesions of the Jaw: A 20-Year Experience at Massachusetts General HospitalQ39619726
Adjuvant antiangiogenic therapy for giant cell tumors of the jawsQ40438612
Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents.Q41018967
Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissuesQ41552807
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer ImmunotherapyQ41809391
Cancer immunotherapy trials: leading a paradigm shift in drug developmentQ42414063
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastasesQ43136029
Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone.Q44788378
Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3.Q46739835
At the crossroads of cancerQ46800604
The highly prevalent H3F3A mutation in giant cell tumours of bone is not shared by sporadic central giant cell lesion of the jaws.Q54183171
A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cells.Q54324671
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.Q54339544
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of BoneQ57570810
P407language of work or nameEnglishQ1860
P577publication date2017-07-19
P1433published inClinical Orthopaedics and Related ResearchQ5133783
P1476titleImmune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone

Reverse relations

cites work (P2860)
Q52561316Letter to the Editor: Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
Q90326654Profiling targetable immune checkpoints in osteosarcoma
Q88482675Reply to the Letter to the Editor: Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone
Q54974872STAT1, IGF1, RAC1, and MDM2 Are Associated with Recurrence of Giant Cell Tumor of Bone.

Search more.